Third Rock Ventures
Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease and autoimmune disease. Prior to Moderna, he was co-head of the US biotechnology investment banking effort at Goldman Sachs. He was a member of the Healthcare Investment Banking Group for nearly fourteen years. Lorence joined Goldman Sachs in 1999 as a summer associate, and was named managing director in 2008.
Among his M&A transactions are the sales of MedImmune to AstraZeneca for $15.6 bn, Millennium to Takeda for $8.8 bn, Human Genome Sciences to GlaxoSmithKline for $3.6 bn, Abgenix to Amgen for $2.9 bn, Medarex to Bristol-Myers Squibb for $2.5 bn, Myogen to Gilead for $2.5 bn, and Micromet to Amgen for $1.2 bn. His recent financings include transactions for Auxilium, Isis, Human Genome Sciences, Regeneron, Medarex, Cubist and Micromet.
Prior to joining Goldman Sachs, Lorence worked in various medical research and consulting positions concurrent with his graduate studies.
Lorence earned an AB in Biochemical Sciences, magna cum laude and Phi Beta Kappa, from Harvard University in 1995. He earned an MBA in Healthcare Management as a Palmer Scholar from the Wharton School of the University of Pennsylvania in 2000 and an MD from the University of Pennsylvania School of Medicine in 2000. He and his wife, Sherry, have three children and live in New York City.